HOFFMANN-LA ROCHE
PASEDENA
This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients.
Status: ACTIVE, NOT RECRUITING
HOFFMANN-LA ROCHE
PADOVA
This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients. This is a 5-year extension study to PASEDENA.
Status: ACTIVE, NOT RECRUITING
Azilect
Rasagiline
Rasagiline is a propargylamine-based medication indicated to treat Parkinson’s Disease.
Status: Completed
FDA Approved
ACADIA
Pimavanserin
Pimavanserin is indicated to treat psychosis in patients with Parkinson’s Disease.
Status: Completed
FDA Approved